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Advanced cases of epithelial, primary peritoneal, and primary tubal malignancies have relative poor
prognosis and collectively remain the most deadly of all gynecologic malignancies. Recently, many
studies have demonstrated that the fallopian tubes might be the origin of most high grade ovarian and
peritoneal serous carcinoma. In this review, we describe the tubal carcinogenic pathway with the pre-
cancerous tubal lesions and the impact of salpingectomy for prevention of ovarian carcinoma.
Copyright © 2015, The Asia-Paciﬁc Association for Gynecologic Endoscopy and Minimally Invasive
Therapy. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
To prevent ovarian carcinoma, you have to remove the ovaries
and not the adjacent fallopian tubes. This has been challenged in
the literature recently. Now the focus of prevention of high grade
serous ovarian carcinoma has shifted from the ovary to the fallo-
pian tubes. In view of the recent description of precancerous tubal
lesion, the majority of pelvic serous carcinoma (ovarian and peri-
toneal carcinoma) may arise from the ﬁmbriated end of the fallo-
pian tubes.1e13 First, this ﬁnding could have important implications
for the surgical management of prophylactic oophorectomy in
groups presenting genetic risk of ovarian cancer. Second, it may be
essential for the decision to remove the fallopian tubes at the time
of hysterectomy for other type of pelvic surgery for benign condi-
tions and during female sterilization in the general population.
For many epithelial malignancies, the cell of origin is well
deﬁned with precursor lesions easily identiﬁed. For example, cer-
vical cancer originates from human papilloma virus-infected cells
in the cervical transformation zone14 and adenocarcinoma of the
colon originates in dysplastic lesions within the colonic mucosa. In
contrast to these tumor types, the origins of epithelial ovarian
cancer are not clearly deﬁned. Just as endometriosis has beennterest relevant to this article
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cinoma,15 emerging data suggest that the fallopian tube may play a
critical role in the origin of what has traditionally been classiﬁed as
serous ovarian cancer. In this review, we will discuss the proposed
mechanism of ovarian carcinogenesis by the tubal epithelium and
the emerging role of salpingectomy in the prevention of ovarian
cancer.
Ovarian cancer classiﬁcation and the tubal paradigm
Ovarian cancer is the most lethal gynecologic malignancy. In
2013, it was estimated that there would be >22,000 new diagnoses
and >14,000 deaths from the diseases.16 Although many improve-
ments have been made in surgical techniques and adjuvant treat-
ment, the prognosis of ovarian cancer is poor, with a 5-year survival
rate of only 45%.17 The majority of ovarian cancer is diagnosed in
advanced stages, in part because no screening test exists to detect
preinvasive or early stage disease.
Epithelial ovarian cancer is divided into its histologic subtypes:
serous, mucinous, endometrioid, clear cell, transitional, or any
combination of these (mixed). Serous histology is the most com-
mon, representing 70% of epithelial ovarian cancer.18 Serous tumors
are aggressive and usually present at advanced stage. Although
they respond to surgery and platinum-based chemotherapy, they
usually recur. Although ovarian carcinoma is evidently a terrible
disease: the life time risk of developing ovarian cancer is 1.8% and
the risk for this disease by age 50 years is 1 in 335, rising to about 1
in 65 between the ages of 50 years and 70 years19 in the generally InvasiveTherapy. PublishedbyElsevier TaiwanLLC. This is anopenaccessarticleunder theCC
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about 40% and in BRCA2 carriers, the lifetime risk is about 20%.20
Removing the ovaries cuts those risks by about 80% and annual
risk falls from 1% to 0.2% after an oophorectomy.21
The tubal theory1e10 is based on the following ﬁndings: with
meticulous and thorough histopathologic analysis of specimens
from prophylactic adexectomy for BRCA genetic mutation, between
4% and 17% occult cancers were revealed, 57e100% of which were
located in the distal portion of the tubes.3e8 These occult intra-
epithelial cancerous lesions are termed serous tubal intraepithelial
carcinomas (STICs).They are characterized by epithelial stratiﬁca-
tion, nuclear atypia with an increase in the nuclear cytoplasmic
ratio, loss of nuclear polarity, nuclear pleomorphism, and loss of
ciliated cells.21
Earlier benign lesions are called serous tubal intraepithelial
(STILs) or tubal intraepithelial lesions in transition. STICs and STILs
are most frequently located at the ﬁmbriated end of the fallopian
tubes.11e13 As we will discuss below, the question arises about
whether ﬁmbriectomy should be proposed instead of salpingec-
tomy in prophylactic strategies.
Studies at the molecular level indicate that STICs and high grade
serous ovarian or peritoneal carcinoma are clonally related and
STICs are not metastases from ovarian carcinoma.22
Recently, another precursor has been described and it is termed
secretory cell out growth (SCOUT), which is distributed throughout
the fallopian tubes,22e25 and ﬁnally would provide argument in
favor of salpingectomy instead of ﬁmbriectomy.
All these histopathologic terms (STICs, STILs, and SCOUT) should
now be familiar to clinicians and surgeons because they are, and
will continue to be, increasingly present in pathologic reports. All
the fallopian tubes removed during permanent contraception
should be sent for histological studies, which will help later in
patients' management.
Last but not least, Kim et al26 recently provided experimental
evidence of the tubal origin using amousemodel; they showed that
a high grade serous ovarian cancer could also arise from the fallo-
pian tubes. Moreover, removal of the fallopian tube prevented
cancer initiation, whereas bilateral ovariectomy had no effect.26
Several series of sporadic serous ovarian cancer and primary
serous peritoneal cancers have been analyzed, and STICs were only
present in about 30e60% of cases.27e29 In cases where STICs were
absent, ovarian cancer can arise from the ovary itself and a pre-
cancerous lesion named ovarian epithelial dysplasia has been
described.30e33 Ovarian dysplasia is deﬁned by cytologic and
architectural abnormalities: surface papillomatosis, epithelial
pseudo stratiﬁcation, inclusion cysts, nuclear pleomorphism, and
epithelial invagination.34
Some other theories have been discussed such as the secondary
mullerian system theory proposed by Lauchlan35 and the unifying
hypothesis proposed by Ausperg36 in which ovarian cancer may
arise from the transitional epithelium between the ovarian surface
epithelium and the ﬁmbrial epithelium of the oviduct. It is possible
that the tubal pathway would be preponderant, particularly in
cases of associated genetic risk, whereas the ovarian and tubal
pathways could coexist in sporadic ovarian cancer.37,38
Salpingectomy and implications for prevention
Effective cancer screening programs typically require identiﬁ-
cation of either a precursor lesion or an early stagemalignancy. This
is demonstrated most notably in colon, cervix, and breast cancer
screening. Unfortunately, without a clear precursor lesion or
biomarker, ovarian cancer screening has thus far been unsuccessful
in identifying preinvasive or early stage disease. A large trial
studying ultrasonography and serum cancer antigen (CA)125 forovarian cancer screening in asymptomatic women was unable to
demonstrate efﬁcacy in detecting early stage disease.39 Modiﬁca-
tion to this approach may demonstrate efﬁcacy either following
CA125 overtime rather than at a single point40 or by triaging pa-
tients to ultrasound only if the CA125 is consistently elevated.41
Models have predicted that tubal intraepithelial carcinoma and
early stage disease are likely to be present for at least 4 years before
becoming widely metastatic.42
Due to the role of the fallopian tube in epithelial ovarian cancer,
approaches to gynecologic surgery have already begun to shift.
With the understanding that ovarian carcinogenesis probably be-
gins in the fallopian tube, prevention strategies such as salpingec-
tomy with ovarian conservation are increasingly being studied to
determine whether they will effectively reduce the burden of
ovarian cancer while allowing women to preserve ovarian function.
Risk-reducing surgery for patients with BRCA mutations
currently includes complete excision of the ovaries and fallopian
tubes with serial sectioning. With careful excision and close eval-
uation, rates of occult preinvasive or invasive tubal malignancies in
this population may be as high at 10%.3
Surgical implications may extend beyond prophylactic surgery
for high-risk patients. In the USA, >600,000 hysterectomies are
performed each year and about 55% of hysterectomies are accom-
panied by bilateral salpingo-oophorectomies (BSO) and about one-
third of all 60-year-old women have had a hysterectomy.43 There
has been considerable debate about the risks and beneﬁts of per-
forming a BSO at the time of hysterectomy. The risk of epithelial
ovarian cancer is reduced, but this comes at the expense of the
potential risks of cardiovascular disease, osteoporosis, and even
cognitive impairment seen with early surgical menopause.44 In a
large analysis of >20,000 patients from the Nurses’ Health Study,
all-cause mortality as well as cancer mortality increased in women
who received a BSO.45 The authors concluded that with an expected
life span of 35 years after surgery, for every nine BSOs performed
there was one additional early death.45 It has been demonstrated
that if salpingectomy is performed with great care by preserving
blood vessel integrity in the proximity of the ovarian hilum and in
the context of the mesosalpinx, patients will not have negative
effects on their ovarian function.46 There were no perioperative
complications associated with the procedure attributable to sal-
pingectomy alone.46
With the risk associated with BSO at the time of hysterectomy
for benign disease, it is becoming more apparent that it may be
clinically prudent to leave the ovaries in place for prolonged hor-
mone exposure. However, because the postreproductive fallopian
tube serves little biologic purpose, it may be sensible to perform
only a salpingectomy at the time of surgery. Although no pro-
spective data support this practice, it follows rationally that this has
the potential to reduce the risk of serous carcinomawith little or no
increased morbidity.47 Given that an estimated 80e90% of BRCA-
related ovarian cancers originate in the fallopian tube, consider-
ation might also be given to performing risk reduction salpingec-
tomy, especially in young people, to conserve ovarian function.48
The patient then may have more time to complete childbearing
with the help of in vitro fertilization and does not have to suffer the
consequences of surgical menopause. This approach has no impact
on breast cancer but could be combined with intensive breast
surveillance and chemoprevention.
It has long been noted that bilateral tubal ligation confers some
protection against developing ovarian cancer. Speciﬁcally, in a
meta-analysis of 13 studies, there was a 34% risk reduction in the
development of endometrioid and serous epithelial ovarian can-
cers.49 It is unlikely that tubal ligation surgically removes areas of
STICs found at the ﬁmbriated end of the tube; however, this has not
yet been evaluated.
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The preferred approach for salpingectomy remains minimally
invasive surgery (laparoscopy or robotic surgery).50e52 The surgical
procedure should be preceded by meticulous and complete in-
spection of the whole abdominopelvic cavity. Pelvic washings
should take place systematically, especially in the case of patients
with BRCA mutations53 and there is no advantage to ﬁmbriectomy
alone because SCOUT lesions can occur anywhere in the tube.
During laparoscopy, it is important to use bipolar electro-
coagulation carefully, because diathermy-induced injury in the
fallopian tubes affects the detection of STICs.54e56Future perspectives
In the near future, there may be opportunities to sample the
preinvasive lesions in the fallopian tubes by use of in situ and real
time optical imaging technologies. Confocal microlaparoscopy or
robotics in real time will help the surgeon in the near future to
decide whether salpingectomy is needed or not.34 McAlpine et al57
managed to identify STICs in a preliminary report with auto-
ﬂuorescence imaging.Conclusions
Epithelial ovarian, primary peritoneal and primary tubal carci-
nomas are complex and heterogeneous groups of malignancies that
remain the most deadly of all gynecologic malignancies. Ongoing
research has conﬁrmed there is no one single site or cell type from
which these cancers arise. A majority of serous ovarian carcinomas
appear to have preinvasive lesions in the distal fallopian tubes and
this recent ﬁnding has shifted the paradigm of ovarian carcinoma
carcinogenesis. Complete bilateral salpingectomy as a risk-reducing
strategy in patients with BRCA mutations is an approach worthy of
further investigation and it may be reasonable to consider sal-
pingectomy for all patients undergoing hysterectomy for benign
reasons, and for general populations who seek permanent contra-
ception. For instance, the Gynecologic Oncology of Canada58
already recommends bilateral salpingectomy for patients under-
going hysterectomy or requesting permanent contraception. As we
move forward, new research is still needed to provide insight into
the carcinogenesis and interaction between the tubes and ovaries
and molecular studies may someday ﬁnd more effective screening
strategies.59,60References
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